[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567394":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":51,"collaborators":30,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":30,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":30,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":30,"overallStatus":35,"whyStopped":30,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sodium glycididazole combined with concurrent chemoradiotherapy group","EXPERIMENTAL","Patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy are treated with sodium glycididazole during concurrent chemoradiotherapy.",[13],"Drug: sodium glycididazole",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","sodium glycididazole","Sodium glycididazole is intravenously infused at a dose of 800mg at 60 min before radiotherapy and used on Mondays, Wednesdays and Fridays during radiotherapy.",[9],[21],"Sodium glycididazole combined with concurrent chemoradiotherapy",[23],{"name":24,"affiliation":5,"role":25},"Lei Deng, MD","STUDY_CHAIR",[27],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","010-87787692",null,"dengleipumc@163.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Cancer Hospital Chinese Academy of Medical Sciences","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":50,"phoneExt":30,"email":30},"Zhengang Xu, MD","+86 10 8778 8495",{"type":52,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100567394","phase-2-sodium-glycididazole-reduces-the-adverse-reactions-of-concurrent-chemoradiotherapy-100567394",false,"NCT06667622","Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy","Sodium Glycididazole Reduces Chemoradiotherapy-related Adverse Reactions During Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Patients must have histologically or cytologically confirmed non-small cell lung cancer.\n2. Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.\n3. ECOG PS 0-2\n4. Adequate organ and bone marrow function.\n\nExclusion Criteria:\n\n1. History of previous radiotherapy.\n2. The previous immune-related pneumonitis ≥ grade 2.\n3. Local lesions require surgery.\n4. History of another primary malignancy.\n5. History of active primary immunodeficiency.\n6. Histological findings showed mixed small cell lung cancer and non-small cell lung cancer.\n7. For any unmitigated toxicity during pre-study chemoradiotherapy.","ALL","18 Years","70 Years",{"count":64,"type":65},40,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.",[71],"Chemoradiotherapy","2024-10-30",{"date":74,"type":75},"2024-10-31","ACTUAL",{"date":77,"type":75},"2024-05-29",{"date":79,"type":65},"2026-07-20",{"name":5,"class":6},1]